Literature DB >> 6499905

Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.

H M Norbury, R A Franklin, P K Marrott, S J Warrington.   

Abstract

Indoramin was administered as a single 50 mg oral tablet to 5 elderly (aged 68-71 years) and 6 middle-aged (aged 46-55 years) healthy female volunteers. The mean half life of indoramin in elderly subjects (14.7 +/- 4.8 h, mean +/- SEM) was statistically significantly longer than that seen in middle-aged subjects (5.1 +/- 1.0 h). The mean plasma concentrations of indoramin and mean area under the plasma concentration/time curve were also greater in elderly than in middle-aged subjects, although this did not achieve statistical significance. In many elderly patients, therefore, a reduction in dosage may be required due to the apparent reduction in clearance of indoramin. However, because of the wide inter-subject variability observed in the oral pharmacokinetics of indoramin, individual titration of indoramin dosage in all patients may be desirable.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6499905     DOI: 10.1007/bf00544054

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  The effect of ageing on the hepatic clearance of propranolol.

Authors:  C M Castleden; C F George
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

3.  Pharmacokinetics of indoramin in man.

Authors:  G H Draffan; P J Lewis; J L Firmin; T W Jordan; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

4.  Pharmacokinetics of oral indoramin.

Authors:  G N Volans; D Jeffereys; A N Latham; T Frost
Journal:  Curr Med Res Opin       Date:  1982       Impact factor: 2.580

Review 5.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Studies on the biotransformation of indoramin in the patas monkey.

Authors:  R A Franklin; D M Pierce
Journal:  Xenobiotica       Date:  1981-11       Impact factor: 1.908

7.  Prazosin disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 8.  Drug therapy in the elderly.

Authors:  J G Ouslander
Journal:  Ann Intern Med       Date:  1981-12       Impact factor: 25.391

  8 in total
  7 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.

Authors:  D M Pierce; S E Smith; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

Review 6.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.